ESPE Abstracts

Body Mass Index (BMI) has a high association with body fat percentage and direct association with a higher degree of comorbidities. Categorizing patients only by the degree of obesity, as has been done over time, restricts the possibility of detecting and giving timely treatment to other aspects. The Edmonton Obesity Staging System for Pediatrics (EOSS-P) has been proposed as a tool to categorize obesity not only by BMI, but also by assessing metabolic complications, functional/mechanical limitations, mental health and social environment, thereby helping to create strategies to target treatment based on individual needs. An ambispective, cross-sectional, observational and descriptive study was conducted. The clinical record of 261 pediatric patients diagnosed with obesity in the period from January 2021 to November 2022 in the Child Welfare Unit of the General Hospital of Mexico was evaluated, of which only 80 complied with all the corresponding evaluations. Data were obtained and staging was assigned based on the EOSS-P scale. In order to make an objective assessment of each of the domains, a general instrument was designed that was built using standardized and validated scales for the pediatric population, which were adapted to the reagents that make up the different domains. Since the final EOSS-P score is assigned by the highest score obtained in any of the 4 domains, it was evidenced that 5% of the total sample was classified in stage 1, 33.8% in stage 2, and 61.3% in stage 3. Surprisingly, none of our patients were classified as stage 0. The domains that we found most affected were metabolic and social, since up to 98.7% of patients presented some degree of involvement. It was found that pediatric patients living with obesity are in advanced stages of severity on the EOSS-P scale, making them susceptible to developing severe comorbidities, from early in life regardless of the degree of obesity. Achieving the design of a tool that evaluates through validated scales all aspects of each of the domains of the EOSS-P in our population. This staging can be used in our patients to plan an individualized intervention strategy aimed at their needs, in order to achieve better adherence to treatment and with the aim of improving quality of life in the medium and long term.